Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, specialty drug company Acura Pharmaceuticals (OTC:ACUR) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Acura and see what CAPS investors are saying about the stock right now.

Acura facts

Headquarters (founded)

Palatine, Ill. (1935)

Market Cap

$140 million



Trailing-12-Month EBITDA

($8.4 million)


CEO Robert Jones (since 2011)
CFO Peter Clemens (since 1998)

Return on Equity (average, past 3 years)



$29.3 million / $0


Collegium Pharmaceutical
Pain Therapeutics (NASDAQ: PTIE)
Purdue Pharma

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 36% of the 97 members who have rated Acura believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those Fools, All-Star zzlangerhans, tapped the stock's recent surge as particularly unsustainable:

When is a non-catalyst a catalyst? ... There was never any doubt that Acura would be putting Nexafed on drugstore shelves, the issue has always been whether they will turn anything resembling a profit. The announcement [Monday] today changes absolutely nothing. OTC cold medicines are a pretty low margin business, and I suspect it takes having a hefty number of them to overcome the costs of doing business in the space. ... Nexafed will be priced similarly to branded pseudoephedrine, which means at the top of the tier, and provides no incentive for a buyer over generic pseudoephedrine.

Acura seems to attract a lot of pyramid-minded traders, who love to pile on once the stock gets some upward momentum because there are a lot of greater fools out there. Will they be the same greater fools who rode the share price back down from [$2.50] to [$1.40] after last month's irrational spike?

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.